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Abstract 
Objectives 
To describe clinical effects, circumstances of occurrence, management and outcomes of cases 
of inadvertent administration of medications by an incorrect parenteral route. 
Methods 
Retrospective single-centre consecutive review of parenteral route errors of medications, 
reported to our centre between January 2006-June 2010. We collected demographic data and 
information on medications, route and time of administration, severity of symptoms/signs, 
treatment, and outcome. 
Results 
78 cases (68 adults, 10 children) were available for analysis. The following wrong 
administration routes were recorded: paravenous (51%), intravenous (33%), subcutaneous 
(8%), and others (8%). Medications most frequently involved were iodinated x-ray contrast 
media (11%) and iron infusions (9%). 28% of the patients were asymptomatic and 54% 
showed mild symptoms; moderate and severe symptoms were observed in 9% and 7.7%, 
respectively, and were mostly due to intravenous administration errors. There was no fatal 
outcome. In most symptomatic cases local nonspecific treatment was performed. 
Conclusions 
Enquiries concerning administration of medicines by an incorrect parenteral route were rare, 
and mainly involved iodinated x-ray contrast media and iron infusions. Most events occurred 
in adults and showed a benign clinical course. Although the majority of exposures concerned 
the paravenous route, the occasional severe cases were observed mainly after inadvertent 
intravenous administration. 
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1. Introduction 
Administration of medications is a frequent process in health care facilities and errors may 
occur at different stages, including prescribing, dispensing, preparing, administering and 
monitoring [1-5]. Furthermore, previous studies have shown that medication errors 
encompass different types such as wrong medication, wrong dose, wrong time, and wrong 
route [6-8]. Within the latter group, parenteral administration errors are particularly relevant 
because of the potential risk for serious outcomes [9-11]. However, information in the 
literature about the circumstances and consequences of application of medicines by the wrong 
route is limited and mostly based on single case reports for most specialties. In contrast, in 
oncology, where parenteral administration of highly toxic substances is frequent, a number of 
publications have addressed this issue [12-14].Some of the studies on medication errors were 
performed by poisons centres (PCs), which are reference centres in case of poisoning and  
medication-related problems and often cover a referral population in the range of some 
million people. PCs therefore exert also a centralizing function in collecting and documenting 
cases of administration errors of medications and medicinal products, and in assisting 
clinicians in the management of these events [9,10,15]. Furthermore, the potential reluctance 
of health care professionals to report such events may be mitigated by the fact that PCs are 
not enforcement authorities, and therefore health care providers do not have to be concerned 
about disciplinary actions and medico-legal liability. Nevertheless, it is possible that a 
substantial number of wrong route application cases remain unreported, because medical 
errors are a delicate issue and health professionals may be unwilling to provide information 
[9,16]. Furthermore, it has been suggested that PCs are more likely to be contacted in severe 
cases [9,10], so that mild and moderate cases may be underrepresented in analyses based on 
PCs data. 
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The aim of this study was to describe clinical effects, circumstances of occurrence (i.e. 
daytime and weekday of occurrence, involved hospital departments), management, and 
outcomes of cases of inadvertent parenteral administration of medications reported to the 
Swiss Toxicological Information Centre in order to improve the management in affected 
patients and to contribute to the prevention of these errors. 
 
 
2. Methods 
2.1 Data acquisition 
The Swiss Toxicological Information Centre (STIC) provides nationwide free 24/7 medical 
advice in cases of poisoning to health professionals and the general public. The referral 
population is about 7.9 million people. Demographic and detailed clinical information on 
exposed cases including age (children defined as ≤ 16 y), sex, and weight of the patient, 
circumstances of poisoning, doses of all substances involved, symptoms/signs, and causality 
are recorded in a systematic and standardized manner by a physician trained in clinical 
toxicology and blinded to any study hypotheses at the time of the initial phone call. These 
data are prospectively entered into an in-house structured electronic database. For reports by 
health care professionals, the STIC collects additional specific clinical data – including 
complementary information on type and, if applicable, concentration of the substances 
involved, current history and circumstances of substance intake, observed symptoms and 
signs, Glasgow Coma Scale (GCS) score, electrocardiography results, therapeutic 
interventions and any decontamination measures performed, latency to decontamination, 
observed clinical course, and eventual medical complications - using a standardized report 
form which is sent to the treating physician. Hospital physicians are also asked to provide a 
discharge letter and any laboratory results, as well as the results of other examinations. This 
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follow-up information is then matched with the data taken during the initial call and entered 
into the database to complement the case files. At this stage evaluation of severity and 
causality is performed. Each case is then reviewed by a senior clinical toxicologist to ensure 
completeness and correctness of entered data before finalizing recording into the database. 
 
2.2 Study design 
We performed a retrospective single-centre consecutive review of parenteral route errors 
(PREs) of medications – defined as errors involving the administration of medications or 
medicinal products (e.g. contrast media, disinfectants, diagnostic medications) by an incorrect 
parenteral route and caused by a qualified medical person (medical doctor, nurse and other 
health care professional) – in humans (children and adults), which were reported to the STIC 
between January 2006 and June 2010. 
 
2.3 Study population 
Between January 2006 and June 2010 the STIC recorded a total of 121,989 human exposures 
to toxic substances in the PC database. Based on this population, a search for the following 
terms (at least one) “paravenous”, “extravasation”, “inadvertent”, “by mistake”, “instead”, 
“erroneous”, “by accident”, and “confusion” was performed and revealed 127 cases of 
parenteral wrong route administrations, fulfilling the inclusion/exclusion criteria (see below). 
From the 127 cases, 49 were excluded because written feedback from the treating physician 
was lacking, leaving 78 cases for further analysis. 
 
2.4 Inclusion and exclusion criteria 
The following criteria had to be met for reported cases to be included in the study: 
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• Route of administration: parenteral (i.e. intravenous, paravenous, intra-arterial, 
subcutaneous, intramuscular, intraperitoneal, intrathecal); 
• Case description by a qualified medical person with written feedback from the treating 
physician with sufficient information about symptoms/signs, clinical course, and 
outcome; 
• Good evidence for exposure (i.e. observed incorrect administration and/or 
characteristic local symptoms); 
• High degree of causal relationship between exposure and clinical effect (for 
symptomatic cases): cases in which other causes for the observed symptoms and signs 
were excluded, or considered less likely than the PRE. 
Each case was reviewed in detail and independently assessed by an expert panel including 
two pharmacists, a clinical toxicologist, and a clinical pharmacologist and general internist. 
Any disagreement in case assessment was resolved by consensus. 
 
Exclusion criteria were: 
• Administration of a medication or medicinal product to the wrong patient but by the 
right application route; 
• Self-injection of veterinary medicines by veterinary doctor or other qualified person; 
• Non-parenteral and other application routes (i.e. oral, rectal, nasal, ocular, vaginal, 
cutaneous, inhalational); 
• Suicidal intent. 
 
2.5 Data processing and classification 
Data were extracted into a standardized Excel spreadsheet format, and categorized into age 
groups, medications involved (according to the Anatomic Therapeutic Chemical (ATC) 
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classification system [17]), routes and times of administration, and severity of symptoms and 
signs. The severity of symptoms was graded in accordance with the Poisoning Severity Score 
(PSS) developed by the European Association of Poisons Centres and Clinical Toxicologists, 
the WHO International Program on Chemical Safety (IPCS), and the European Commission 
[18]: ‘minor’, for mild, transient and spontaneously resolving symptoms/signs; ‘moderate’, if 
at least one pronounced or prolonged symptom/sign was recorded; ‘severe’ if at least one 
severe or life-threatening symptom/sign was observed, or `fatal` if the administration error 
was the recorded cause of death. 
 
2.6 Statistical evaluation 
Statistical analysis for descriptive statistics was performed using the SPSS software package 
(version 18.0; SPSS Inc., Chicago, IL, USA). 
 
2.7 Ethical approval 
Informed consent from patients or ethics approval was not necessary due to the nature of the 
study design according to the regulations of the cantonal ethics committee Zurich. 
 
 
3. Results 
3.1 Patient characteristics 
Demographic characteristics of the 78 patients included in the study were as follows: 68 
adults (87%) with a mean age of 57.9 years (SD 19, median 58.5, range 20–89) and 10 
children with a mean age of 4.1 years (SD 2.6, median 4.1, range 7 days–7.2 years, ). In 4 
cases, age could not be determined, but the attribution to an age group (child/adult) was 
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possible. Both genders were almost equally represented among adults and children (i.e. in 
total 41 males (53%), 36 females (46%), and one case with unspecified gender). 
 
3.2 Medications / Medicinal products 
An overview of the medications involved in PRE (grouped according to their ATC 
classification) is presented in Table 1. In 90% of the cases only one medication was 
administered. Iodinated x-ray contrast media (9 cases, 11.5%) were most frequently involved, 
followed by iron infusions (7 cases, 9.0%), and phenytoin (4 cases, 5.1%). Disinfectants were 
the only dermatologicals applied by the wrong route in the study population. Other substances 
included hydrochloric acid (used for correction of metabolic alkalosis), methanol (0.05ml 
inadvertently administered during scintigraphy), hydrogen peroxide (erroneously 
administered during local anesthesia), phenol (used as caustic agent for nail extraction), 
sodium hydrogencarbonate (used inadvertently instead of lidocaine for local anesthesia), and 
ethylenediamine-tetracetic acid (EDTA; reflux of blood into a vein from an EDTA-containing 
blood collection tube). 
 
3.3 Severity and routes of administration 
Most patients had mild symptoms or were asymptomatic (Table 2). Severe symptoms were 
recorded in 6 cases (7.7%) (Table 3), and no fatal outcome was reported. In 40 cases (51.3%) 
the route was paravenous. Among these, 5 (12.5%) were asymptomatic, 31 (77.5%) showed 
mild, and 3 (7.5%) moderate or severe symptoms. In one case severity could not be 
determined definitively because information about clinical course was incomplete. 
Inadvertent intravenous administration occurred in 26 cases (33%). In 14 (53.8%) of these, 
patients remained asymptomatic, whereas 5 (19.2%) patients showed mild and 7 (27%) 
moderate or severe symptoms. Severe symptoms were observed in one, and mild in 5 of the 6 
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inadvertent subcutaneous administration cases. No symptoms were reported in the 2 
inadvertent intramuscular application cases, and in the one with a combined intramuscular 
and perineural administration. Inadvertent intra-arterial applications resulted in severe 
symptoms in one case and in mild in the other. Moderate symptoms occurred after 
extravasation from a Port-A-Cath into the pleural space. 
 
3.4 Symptoms, signs, and outcomes 
Symptoms and signs observed after paravenous or subcutaneous incorrect route 
administrations consisted mainly of minor local discomfort, e.g. swelling (25 cases), pain 
(14), redness (12), burning (3), and hematoma formation (3). This also applies to the cases of 
paravenous iron administration, in which symptoms like transient swelling (5 cases), 
hematoma formation (3), pain (2), and redness (1) were recorded. In cases of inadvertent 
intravenous administration, patients were either asymptomatic (14 cases) or showed moderate 
to severe systemic reactions (7) such as tachycardia, hypertension, and ischemic alterations of 
the ECG after an incorrect administration of epinephrine, or tachycardia and hypotension after 
the incorrect application of inhalatory solutions containing salbutamol and ipratropium 
bromide. Among the 6 severe cases in this study (Table 3), the 3 patients with the intravenous 
and the one with the intra-arterial administration error showed systemic symptoms including 
coma, convulsions, and circulatory failure. The remaining 2 patients with severe outcome 
developed local tissue necrosis - one after a paravenous and one after a subcutaneous 
administration error. 
In 58 cases (74%) there were no permanent sequelae. In contrast, in 5 patients (6.4%) 
symptoms persisted for at least several days and consisted of sensory disturbances in the right 
upper extremity in one case (extravasation of cefuroxime, morphine, and acetaminophen from 
a central venous catheter), tingling paraesthesia of the fingertips of one hand in another case 
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(paravenous administration of an iron containing medication), swelling and erythema in the 
chest area in a third case (extravasation of paclitaxel from a Port-A-Cath), and local tissue 
necrosis in two cases requiring surgical intervention (paravasation of phenytoin) and toe 
amputation (extravasation of phenol), respectively. In 15 cases (19%) data regarding outcome 
was incomplete. 
 
3.5 Treatments 
In most symptomatic cases local unspecific treatment was performed, i.e. cooling (10 cases, 
12.8%), immobilization and/or elevated positioning (9 cases, 11.5%), application of a heparin 
or cortisone containing cream (5 cases, 6.4%), or compression dressings (3 cases, 3.8%). Oral 
antibiotics were administered in the case of subcutaneous phenol injection with subsequent 
toe necrosis, and in a case of iron paravasation. Intravenous antibiotics were given 
prophylactically in an immunosuppressed patient after the erroneous i.v. administration of an 
oral methadone solution. In the case of inadvertent i.v. application of polyhexanide, 
hemodialysis was performed in order to enhance removal of the substance according to the 
literature [19]. In the case of extravasation of vincristine from a Port-A-Cath into the pleural 
space, pleural lavage was performed with good results. 
 
3.6 Setting, origin of enquiries, and involved hospital departments 
In 69 cases (88%) enquiries originated from hospital doctors, the remaining 9 (12%) were 
from physicians in private practices. The following hospital departments were mainly 
involved: internal medicine (21 cases, 27.0%), surgery (9, 11.5%), pediatrics (7, 9%), and 
oncology (4, 5.1%). Eleven (16%) of the hospital cases occurred in emergency departments 
and 6 (7.7%) in intensive care units. In 10 (21%) cases the department was not reported. 
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3.7 Daytime and weekday of occurrence 
Analysis of PRE in relation to daytime revealed that these events occurred during the whole 
day, including night-time. A clear peak at a certain daytime was not observed, although cases 
were rarer during the night. Inadvertent intravenous applications appeared to happen mainly 
during the morning and around midday, whereas paravasations seemed to occur more 
frequently in the afternoon and evening. Among the 54 cases in which the exposition time 
was known (and not only the time of call), 44 enquiries (82%) occurred within 3 hours of the 
event. No specific relationship between administration errors and day of the week or month 
was observed. 
 
 
4. Discussion 
Enquiries to our centre concerning administration of medicines and other medicinal products 
by an incorrect parenteral route were rare, and this is in accordance with previous reports 
from other PCs, although settings were comparable to a limited extent. Actually, two studies 
from Germany (only intravenous wrong route) found a frequency of 0.03% [9] and 0.01% 
[10], respectively, a Finnish study (erroneous route in general) of 0.04% [20], and an Irish 
study (erroneous route in general) of 0.5% [21]. Nevertheless, a detailed analysis is important 
and appropriate since every case may deliver new insights into the circumstances of 
occurrence, resulting symptoms, treatment options, and outcomes, and therefore enable the 
identification of at-risk situations, with the subsequent possibility to implement effective 
prevention strategies. Moreover, since experimental study designs would be unethical in this 
context, and since evidence is scarce for most recommended treatments, such analyses may 
provide significant information to improve clinical case management. 
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The follow-up rate of the cases in this study was remarkably high compared to previous 
analyses [9,10], despite the potential reluctance of health care professionals to report such 
events, and this may have improved the completeness and overall quality of our data. 
In spite of the perceived risk of serious outcomes [9-11], most cases in this study showed a 
benign clinical course, which is compatible with the results obtained by Deters et al. when 
analyzing intravenous administration errors [10]. Nevertheless, it is important to recognize 
that the consequences of incorrect route administration errors are influenced by several 
factors, such as the specific application route, the amount administered and the characteristics 
of involved medications, and – if applicable – the duration of tissue exposure [22]. 
Although the majority of exposures concerned the paravenous route, severe cases were 
mainly observed after erroneous intravenous administration possibly due to the rapid 
achievement of high serum concentrations with subsequent systemic effects. A severe 
outcome seems also plausible after inadvertent intra-arterial administration. Unfortunately, 
there were not enough cases in this study to substantiate this hypothesis. 
The medicines most commonly involved in the study population (x-ray contrast media and 
iron containing products), differ considerably from the ones identified in the studies by Deters 
et al. [9,10] (antipsychotics, antihistamines for systemic use, and adrenergics for systemic use 
in the first study, and antipsychotics, antiseptics/disinfectants, and antihistamines for systemic 
use in the second, respectively). Remarkable differences are also evident in comparison to a 
study on wrong route administrations in five Brazilian hospitals [23], where cardiovascular 
agents, followed by medications acting on the nervous system and the digestive tract and 
metabolism, respectively, were most commonly involved. Different inclusion criteria may 
explain the observed differences. Actually, the first two studies focused on medication errors 
by the intravenous route and also analyzed overdose cases, whereas the last one also included 
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administration errors by the enteral route. Furthermore, the nature of cases in our study 
population is subject to selected reporting, which may also explain such differences. 
In our study, all PREs involving contrast media had a benign course without sequelae, and 
this is in line with the findings of Sbitany et al. [24] and Wang et al. [25]. This is probably 
due to the progressively increased use of low-osmolality, non-ionic contrast media, which do 
not cause serious injuries in case of extravasation [26]. Regarding the second most commonly 
involved medication, i.e. iron containing products, information concerning extravasation is 
scarce in the literature. The product information indicates that in case of paravenous 
application, a brown discoloration of the skin at the injection site and a local irritation may 
occur. This is in contrast to our findings, where patients showed symptoms and signs such as 
swelling, pain, and redness. Unexpectedly, only a few cases of extravasation of oncologic 
medications were reported to our centre. This could be explained by the fact that specialized 
nursing and medical staff in oncology units is familiar with these situations, which have been 
extensively discussed in the literature [12,13,27,28]. 
In most of our cases, symptomatic treatment was sufficient for both local and systemic 
reactions. Specific treatments - e.g. hemodialysis, surgical debridement - were required only 
in a few cases. No specific antidote treatment was needed except for one case in which 
naloxone was administered (Table 3, case 1). Unfortunately, a more detailed analysis of 
treatment approaches and their efficacy was not possible due to the limited number of cases in 
this study. 
Most enquiries to our centre were from hospitals and only a few from private practices. 
Among the former institutions, PREs were relatively rarely reported from emergency 
departments and intensive care units, which appears surprising considering the stressful 
working conditions in these units, and the complexity of patients with multiple comorbidities 
and pharmacological treatments. This observation might be explained by the special training 
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of nursing and medical staff in these units [29], and, possibly, by the more standardized 
algorithm-based approach with a frequent use of safety checklists in the critical care setting. 
Accordingly, Kane-Gill [29] observed that administration errors occurred mainly on general 
wards, whereas on intensive care units prescribing errors predominated. However we 
acknowledge that the issue of the frequency of medical errors in the critical care setting is 
controversially discussed in medical literature [30,31] and our findings might also be 
influenced by other factors such as underreporting as a consequence of fear of punitive 
measures [32,33]. In our study, most administration errors occurred on the wards, where work 
under time pressure due to shortage of personnel and heavy workload are recognized risk 
factors [34]. Although this has not been specifically addressed in our study, a standardized 
approach to administration of medications with a more frequent use of safety checklists seems 
reasonable and should be recommended for all levels of care. 
The interpretation of our findings is limited by the retrospective nature of the study design 
and by the low number and heterogeneity of the cases available for analysis. This implies that 
detailed information that may be relevant might not have been recorded at the time of the 
initial call. In addition, PC’s data are subject to reporting bias, as it has been previously 
described [35]. Underreporting may particularly be an issue when studying medication errors, 
because the fear of disciplinary actions and legal consequences may limit reporting of such 
cases. On the other hand, the perceived risk of serious outcomes could prompt health care 
professionals to ask for advice, and this may be especially true for cases in which severe 
symptoms and signs have developed, potentially biasing the results towards higher percentage 
of severe cases. 
 
5. Conclusions 
 15/22 
In conclusion, enquiries to our centre concerning administration of medicines or medicinal 
products by an incorrect parenteral route were rare, and mainly involved iodinated x-ray 
contrast media and iron containing products. Most events occurred in adults and showed a 
benign clinical course with complete recovery. Although the majority of exposures concerned 
the paravenous route, the occasional severe cases were observed mainly after inadvertent 
intravenous administration. In most cases, enquiries originated from hospital doctors of the 
following departments: internal medicine, surgery, pediatrics, and oncology. 
We recommend particular attention should be paid when administering iron infusions and 
contrast media. In case of erroneous application of a medication by an intravenous route, 
close monitoring of the patient is advised. The implementation of preventive strategies seems 
advisable, especially on internal medicine wards.  
To investigate the problem of medication wrong route administration in more detail, a 
prospective study, which would allow collecting data in a more structured way and therefore 
provide more complete information about the cases, is planned at our centre. 
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List of abbreviations 
STIC  Swiss Toxicological Information Centre 
PRE  Parenteral Route Error 
ATC  Anatomic Therapeutic Chemical 
PSS  Poisoning Severity Score 
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Table 1. Groups of medications and medicinal products involved in parenteral wrong route application cases in 
relation to the administration route 
Medication group / Medicinal products 
(ATC code in parentheses) 
Para-
venous 
Intra-
venous 
Subcuta-
neous 
Intra-
arterial 
Intra-
muscular Other Total 
Nervous system (N) 6 9 1 1   17 (21.8%) 
Blood and blood-forming organs (B) 10 1 1  1  13 (16.6%) 
Various (V) (mainly contrast media) 9 2     11 (14.1%) 
Anti-infectives for systemic use (J) 8   1     9 (11.5%) 
Medicinal products (e.g. alcohol, soap) 1 2 3      6   (7.7%) 
Anti-neoplastic and immuno-modulating 
agents (L) 3     1   4   (5.1%) 
Musculo-skeletal system (M) 3    1    4   (5.1%) 
Respiratory system (R)  4       4   (5.1%) 
Alimentary tract and metabolism (A)  3       3   (3.9%) 
Dermatologicals (D)  1 1   1   3   (3.9%) 
Systemic hormonal preparations (H)  3       3   (3.9%) 
Cardiovascular system (C)  1       1   (1.3%) 
Total 40 26 6 2 2 2 78  (100%) 
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Table 2. Severity of cases of parenteral wrong route administration in relation to patient characteristics 
(percentages in parentheses) 
  Severity of symptoms  
Age Gender None Minor Moderate Severe Not classifiable Total (%) 
Adults Male 12 17 3 2 1 35 (44.9) 
 Female 8 18 2 4 0 32    (41) 
 Unknown 0 1 0 0 0   1   (1.3) 
 Subtotal 20 36 5 6 1 68  (87.2) 
Children Male 2 4 0 0 0   6    (7.7) 
(≤ 16 y/o) Female 0 2 2 0 0   4    (5.1) 
 Subtotal 2 6 2 0 0 10  (12.8) 
Total (%)  22 (28) 42 (54) 7 (9) 6 (7.7) 1 (1.3) 78  (100) 
 
 
